先健科技:2023年度報告
Lifetech Scientific Buys Shares For Employee Incentive Scheme
Lifetech Scientific (HKG:1302) has agreed to acquire 21.7 million shares for its share award scheme, according to a Wednesday filing on the Hong Kong bourse. The company will purchase the shares from
Xianjian Technology: The trustee purchased 21.72 million shares in connection with the share award program
Xianjian Technology (01302) issued an announcement. On April 10, 2024, the trustee, the seller and the company signed the agreement. According to this, for the share award plan, the trustee (as directed by the company) agreed to buy (funded by the company) and the seller agreed to sell 21.72 million shares.
Xianjian Technology (01302.HK): The trustee purchased 21.72 million shares in connection with the share award program
Gelonghui, April 10, 丨 Xianjian Technology (01302.HK) announced that on April 10, 2024, the trustee, seller and company entered into the agreement. According to this, for the share award plan, the trustee (with instructions from the company) agreed to buy (funded by the company) and the seller agreed to sell 21.72 million shares. The price of the shares to be sold was HK$1.750 per share to be sold. The purpose of adopting the share award scheme is to recognize, motivate and reward the contributions made by a number of eligible participants in order to maintain their continued effectiveness in the Group's operations and development.
Press Release: LifeTech Scientific Corporation Announced 2023 Annual Results: International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid Development
LifeTech Scientific Corporation Announced 2023 Annual Results: International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid Development PR Newswire SHENZHEN, China, Apr
Xianjian Technology (01302.HK) subscribes to a capital protected structured deposit
Gelonghui, April 2, 丨 Xianjian Technology (01302.HK) announced that Xianjian Shenzhen, a wholly-owned subsidiary of the company, and Bank of Ningbo have signed such structured deposit agreements between January 12, 2023 and March 28, 2024. According to this, Xianjian Shenzhen subscribes to capital protected floating income structured deposits issued by Bank of Ningbo, with a total principal amount of RMB 340 million.
Lifetech Scientific Books Lower 2023 Profit Despite Surge in Revenue
Lifetech Scientific (HKG:1302) posted a net profit attributable to owners of about 263.2 million yuan for the year ended Dec. 31, 2023, down from 325.3 million yuan in the previous year, according to
Xianjian Technology (01302) announced annual results. Profit attributable to shareholders of 263 million yuan decreased by 19.09% year-on-year
According to the Zhitong Finance App, Xianjian Technology (01302) announced the results for the year ended December 31, 2023. The group obtained revenue of RMB 1,267 billion (same unit), an increase of 15.48% over the previous year; profit attributable to the company owners was 263 million yuan, a decrease of 19.09% over the previous year; and the basic profit per share was 6 points. According to the announcement, the increase in revenue was mainly due to increased revenue from sales of congenital heart disease occulators and laminated stents.
LIFETECH SCI: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
LifeTech Scientific Flags Significant Profit Drop in 2023
LifeTech Scientific (HKG:1302) expects to record a "significant" decline in net profit for the year ended December 2023 when compared to 2022, according to a Friday filing with the Hong Kong bourse. T
Xianjian Technology (01302) issued a profit warning. Annual net profit is expected to drop significantly year-on-year
Xianjian Technology (01302) announced that the Group's net profit for the year ended December 31, 2023 is expected to be 2...
先健科技:盈利預警
LIFETECH SCI: NOTICE OF BOARD MEETING
Southwest Securities: There is still a lot of room for penetration in the coronary artery disease interventional treatment market, focus on Sano Healthcare (688108.SH), etc.
Coronary heart disease is the leading cause of death in the world, and there is still plenty of room for penetration in the interventional treatment market for coronary artery disease in China.
Germany to Approve Cannabis Bill This Week in Legalization Drive
German lawmakers will approve delayed legislation decriminalizing personal use of cannabis this week, paving the way for it to take effect on April 1, according to Health Minister Karl Lauterbach.
LifeTech Scientific Corporation (HKG:1302) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
LifeTech Scientific Corporation (HKG:1302) shareholders that were waiting for something to happen have been dealt a blow with a 27% share price drop in the last month. Instead of being rewarded, sh
LifeTech Scientific to Grant 174.8 Million Share Options
LifeTech Scientific (HKG:1302) directors will grant 174,750,000 share options to 226 participants at HK$1.95 apiece, a Wednesday filing said. Among the participants are directors, C-level personnel, a
Xianjian Technology granted a total of 175 million share options
Xianjian Technology (01320) issued an announcement. The board of directors decided to grant a total of 175 million share options and was granted to 226 eligible participants in accordance with the share option plan adopted by the company on September 17, 2021. They are group directors, top executives, major shareholders or employees, and can subscribe to the company's share capital, totaling 175 million shares of common shares with a face value of $0.00,000,125 per share. The exercise price of the share options granted was HK$1.95 per share.
The Three-year Underlying Earnings Growth at LifeTech Scientific (HKG:1302) Is Promising, but the Shareholders Are Still in the Red Over That Time
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long term LifeTech Scientific Corporation (HKG:1302) shareholders know that all too
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
No Data